
Oxford Immunotec Global PLC OXFD
Oxford Immunotec Global PLC Financial Ratios 2011-2026 | OXFD
Annual Financial Ratios Oxford Immunotec Global PLC
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | -232.5 | 3.1 | -8.5 | -13.2 | -10.3 | -9.2 | -9.1 | - | - |
P/S |
- | 5.7 | 6.2 | 2.7 | 3.4 | 4.0 | 4.1 | 2.0 | - | - |
EV/EBITDA |
- | -73.4 | -11.0 | -8.9 | -11.9 | -7.7 | -7.7 | -0.5 | - | - |
PEG |
- | 2.29 | 0.01 | 0.22 | -1.23 | -0.83 | -0.21 | 0.35 | - | - |
P/B |
- | 2.0 | 1.7 | 3.2 | 4.0 | 2.7 | 3.4 | 1.0 | - | - |
P/CF |
- | -47.7 | -16.2 | -32.3 | -12.1 | -12.6 | -8.4 | -10.3 | - | - |
ROE % |
- | -0.85 | 56.44 | -37.53 | -30.63 | -26.41 | -36.59 | -10.73 | - | - |
ROA % |
- | -0.77 | 52.03 | -22.80 | -18.02 | -22.28 | -30.03 | -9.34 | - | - |
ROCE % |
- | -2.26 | -8.24 | -23.59 | -24.09 | -25.62 | -35.10 | -9.01 | - | - |
DSO |
- | 90.8 | 83.4 | 60.1 | 56.2 | 41.0 | 50.3 | 44.7 | - | - |
DIO |
- | 210.0 | 168.5 | 79.2 | 68.8 | 87.7 | 97.7 | 106.9 | - | - |
DPO |
- | 45.8 | 60.8 | 53.4 | 29.6 | 46.9 | 36.0 | 45.3 | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Oxford Immunotec Global PLC, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
$ 2.87 | -3.04 % | $ 93.1 K | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
$ 118.59 | 0.39 % | $ 36.1 B | ||
|
Celcuity
CELC
|
$ 108.89 | 0.54 % | $ 4.3 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
$ 27.69 | -1.07 % | $ 769 M | ||
|
Charles River Laboratories International
CRL
|
$ 175.98 | -1.49 % | $ 8.72 B | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
$ 13.9 | -2.11 % | $ 420 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
$ 16.01 | 1.62 % | $ 2.08 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
$ 1.11 | -2.63 % | $ 1.41 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 209.65 | -0.29 % | $ 23.3 B | ||
|
Danaher Corporation
DHR
|
$ 203.85 | -0.99 % | $ 145 B | ||
|
Exact Sciences Corporation
EXAS
|
$ 103.36 | 0.01 % | $ 19.5 B | ||
|
Bioventus
BVS
|
$ 8.85 | 0.91 % | $ 554 M | ||
|
DarioHealth Corp.
DRIO
|
$ 10.3 | -4.19 % | $ 292 M | ||
|
DexCom
DXCM
|
$ 73.26 | -0.7 % | $ 28.6 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
Burning Rock Biotech Limited
BNR
|
$ 24.01 | -4.59 % | $ 254 M | ||
|
VolitionRx Limited
VNRX
|
$ 0.2 | -2.17 % | $ 19.2 M | ||
|
CareDx, Inc
CDNA
|
$ 18.74 | -0.03 % | $ 999 M | ||
|
ICON Public Limited Company
ICLR
|
$ 108.07 | -0.18 % | $ 8.91 B | ||
|
IDEXX Laboratories
IDXX
|
$ 639.3 | 0.41 % | $ 51.4 B | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Illumina
ILMN
|
$ 130.84 | -1.54 % | $ 20.8 B | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Guardant Health
GH
|
$ 94.83 | 2.82 % | $ 11.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 283.93 | -0.81 % | $ 23.6 B | ||
|
Lantheus Holdings
LNTH
|
$ 79.25 | 3.87 % | $ 5.35 B | ||
|
IQVIA Holdings
IQV
|
$ 174.04 | -0.14 % | $ 29.9 B | ||
|
Brainsway Ltd.
BWAY
|
$ 23.08 | -2.57 % | $ 99.4 M | ||
|
Co-Diagnostics
CODX
|
- | - | $ 79.8 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 317.21 | -0.44 % | $ 27.1 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Myriad Genetics
MYGN
|
$ 5.32 | 6.19 % | $ 493 M | ||
|
NeoGenomics
NEO
|
$ 9.71 | 2.21 % | $ 1.24 B | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
$ 209.59 | 4.71 % | $ 20.6 B | ||
|
Pacific Biosciences of California
PACB
|
$ 1.55 | -4.63 % | $ 465 M | ||
|
Neogen Corporation
NEOG
|
$ 11.01 | -1.26 % | $ 2.39 B | ||
|
Precipio
PRPO
|
$ 24.7 | 0.08 % | $ 32.1 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B |